These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6595058)

  • 1. Phase II evaluation of 4'-epi-doxorubicin in patients with metastatic colorectal carcinoma.
    Ajani JA; Kanojia MD; Bodey GP
    Cancer Treat Rep; 1984 Dec; 68(12):1507-8. PubMed ID: 6595058
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II evaluation of 4'-epi-doxorubicin in patients with advanced colorectal carcinoma.
    Michaelson R; Kemeny N; Young C
    Cancer Treat Rep; 1982 Sep; 66(9):1757-8. PubMed ID: 6956441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of 4'-epi-doxorubicin in advanced colorectal carcinoma: a Northern California Oncology Group study.
    Meyers FJ; Lewis B; Mitchell E; William L; Hannigan JF; Gribble M; Torti FM
    Cancer Treat Rep; 1985 Jan; 69(1):143-4. PubMed ID: 3855385
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II trial of 4'-epi-doxorubicin in metastatic melanoma.
    Torti FM; Porzig KJ; Gandara DR; Volberding P; Mitchell E; Meyers FJ; Kohler M; Gribble M
    Cancer Treat Rep; 1984 Dec; 68(12):1509-10. PubMed ID: 6595059
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II trial of esorubicin in patients with advanced colorectal carcinoma.
    Fiore J; Kemeny N; Raymond V; Young C
    Cancer Treat Rep; 1986 Oct; 70(10):1241-2. PubMed ID: 3530453
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II trial of 4'-epi-doxorubicin in metastatic colorectal carcinoma.
    Wils JA
    Invest New Drugs; 1984; 2(4):397-9. PubMed ID: 6595243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II evaluation of pyrazofurin in patients with advanced colorectal carcinoma.
    Carroll DS; Kemeny NE; Gralla RJ
    Cancer Treat Rep; 1979 Jan; 63(1):139-40. PubMed ID: 369686
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II trial of bisantrene in advanced colorectal carcinoma.
    Ahmed T; Kemeny NE; Michaelson RA; Harper HD
    Cancer Treat Rep; 1983 Mar; 67(3):307-8. PubMed ID: 6831479
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II study of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: an Illinois Cancer Council Trial.
    Locker GY; Hoeltgen T; Kilton L; Krauss S; McNamara M; Blough R; Johnson C
    Cancer Treat Rep; 1987; 71(7-8):765-6. PubMed ID: 3300969
    [No Abstract]   [Full Text] [Related]  

  • 10. Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC).
    Holdener EE; Hansen HH; Høst H; Bruntsch U; Cavalli F; Renard J; Pinedo HM; Rozencweig M
    Invest New Drugs; 1985; 3(1):63-6. PubMed ID: 3857219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of 4'epi-doxorubicin in patients with metastatic colorectal carcinoma.
    Ferrazzi E; Pappagallo GL; Nicoletto O; Fornasiero A; Refatti F; Cartei G; Vinante O; Fiorentino MV
    Tumori; 1984 Jun; 70(3):297-300. PubMed ID: 6588671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of 4'-epi-doxorubicin in metastatic renal cancer.
    Fosså SD; Wik B; Bae E; Lien HH
    Cancer Treat Rep; 1982 May; 66(5):1219-21. PubMed ID: 6952962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of 4'-epi-doxorubicin in advanced breast cancer.
    Campora E; Nobile MT; Sertoli MR; Rosso R
    Cancer Treat Rep; 1984 Oct; 68(10):1285-6. PubMed ID: 6597003
    [No Abstract]   [Full Text] [Related]  

  • 14. Preliminary echocardiographic and polygraphic evaluation of cardiac toxicity of 4'-epi-doxorubicin.
    Villani F; Comazzi R; Lacaita G; Genitoni V; Guindani A; Martini A
    Int J Clin Pharmacol Ther Toxicol; 1983 Apr; 21(4):203-8. PubMed ID: 6574995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of a 21-day continuous infusion schedule with epirubicin in metastatic colorectal cancer.
    Greidanus J; Willemse PH; Sleijfer DT; Mulder NH; Verschueren RC; Nieweg R; de Vries EG
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):801-2. PubMed ID: 3164271
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II evaluation of metoprine in patients with advanced colorectal carcinoma.
    Lynch G; Kemeny N; Currie V
    Cancer Treat Rep; 1981; 65(1-2):127-8. PubMed ID: 7226162
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced colorectal carcinoma.
    Carroll DS; Kemeny N; Lynch G; Wookcock T
    Cancer Treat Rep; 1980; 64(10-11):1149-50. PubMed ID: 6893951
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II evaluation of metoprine with leucovorin rescue in patients with advanced colorectal carcinoma.
    Lynch G; Currie V; Kemeny N
    Cancer Clin Trials; 1981; 4(3):281-3. PubMed ID: 6974612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study on oral N-methylformamide in metastatic colorectal cancer.
    Planting AS; Klijn JG; Verweij J; Stoter G
    Cancer Treat Rep; 1987 Dec; 71(12):1293-4. PubMed ID: 3690540
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II trial of 4-demethoxydaunorubicin in advanced colorectal carcinoma.
    Harper HD; Kemeny NE; Ahmed T; Cheng E; Arena F; Sordillo P; Faye L
    Cancer Treat Rep; 1984 Apr; 68(4):689-90. PubMed ID: 6585273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.